Sema3C Promotes the Survival and Tumorigenicity of Glioma Stem Cells through Rac1 Activation
Author(s) -
Jianghong Man,
Jocelyn D. Shoemake,
Wenchao Zhou,
Xiaoguang Fang,
Qiulian Wu,
Anthony Rizzo,
Richard A. Prayson,
Shideng Bao,
Jeremy N. Rich,
Jennifer S. Yu
Publication year - 2014
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2014.10.055
Subject(s) - autocrine signalling , paracrine signalling , biology , stem cell , progenitor cell , cancer research , population , gene knockdown , glioma , cancer stem cell , immunology , apoptosis , microbiology and biotechnology , receptor , medicine , genetics , environmental health
Different cancer cell compartments often communicate through soluble factors to facilitate tumor growth. Glioma stem cells (GSCs) are a subset of tumor cells that resist standard therapy to contribute to disease progression. How GSCs employ a distinct secretory program to communicate with and nurture each other over the nonstem tumor cell (NSTC) population is not well defined. Here, we show that GSCs preferentially secrete Sema3C and coordinately express PlexinA2/D1 receptors to activate Rac1/nuclear factor (NF)-κB signaling in an autocrine/paracrine loop to promote their own survival. Importantly, Sema3C is not expressed in neural progenitor cells (NPCs) or NSTCs. Disruption of Sema3C induced apoptosis of GSCs, but not NPCs or NSTCs, and suppressed tumor growth in orthotopic models of glioblastoma. Introduction of activated Rac1 rescued the Sema3C knockdown phenotype in vivo. Our study supports the targeting of Sema3C to break this GSC-specific autocrine/paracrine loop in order to improve glioblastoma treatment, potentially with a high therapeutic index.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom